According to the SMR analysis, genetic variations in the target genes forsulfonylureas (KCNJ11) and SGLT2 inhibitors (SLC5A2) weresignificantly associated with AIS risk (KCNJ11: odds ratio (OR) = 1.11,95% confidence interval (CI) = 1.01–1.21; p = 0.033; SLC5A2:OR = 1.05, 95% CI = 1.01–1.10; p = 0.017). The gene discussed is SLC5A2; the disease is androgen insensitivity syndrome.